Taconic Biosciences Launches huNOG-EXL Mouse Model With Extended Cell Lineages, Providing a Clearer Representation of Human Immune Response
Model Will Transform Immuno-Oncology, Allergy and Inflammation Research
HUDSON, NY--(Marketwired - Feb 2, 2016) - Taconic Biosciences, a leading provider of genetically modified mouse models and associated services to researchers worldwide, announced it has launched the huNOG-EXL, an extended lineage mouse model that will greatly improve immuno-oncology, allergy and inflammation research. Available exclusively from Taconic, the huNOG-EXL incorporates an engrafted human immune system to recapitulate myeloid lineages that are known to play a key role in innate immune responses, resulting in a more complete reflection of human immunity.
"The huNOG-EXL is a major advancement with the potential to greatly enhance researchers' understanding of how human immune response impacts disease and how it can be leveraged to develop targeted therapies," said Dr. Michael Seiler, Associate Director, Genetically Engineered Models Design and Precision Research Models, Taconic Biosciences. "The huNOG-EXL provides a much clearer representation of human immune response and reflects years of development of new in vivo rodent models with more complete immune development, enabling investigators to perform studies that were not feasible in the past."
The huNOG-EXL combines the background of the CIEA NOG mouse® with transgenic low-level expression of two human cytokines (GM-CSF and IL-3), both known to limit myeloid lineage commitment due to cross-species limitations. Upon engraftment with human hematopoietic stem cells, the hGM-CSF/hIL3 transgenic-NOG host results in a human-like immune system that includes mature granulocytes, monocytes, macrophages, B cells and T cells, extending the limits of existing engrafted human immune system models. This precision research model enables the study of key innate mechanisms with direct correlates to safety and efficacy, and is especially useful for immuno-oncology applications.
"The extended reconstitution of immune cell lineages of the huNOG-EXL will allow improved modeling of the complex, heterogeneous tumor micro-environment by favoring the differentiation of cells that can infiltrate the tumor and participate in the immuno-modulatory tumor niche, all of which are high-value targets for immuno-oncology drug discovery," Seiler said. Because the huNOG-EXL is more reflective of innate human immunity than previously available models, it will enable better predictability of clinical outcomes and help speed time-to-market with efficacious therapies.
Taconic offers the huNOG-EXL as an off-the-shelf, in-licensed model to facilitate access and availability. To learn more about the huNOG-EXL, visit http://www.taconic.com/hunog-exl or contact the company at 1-888-TACONIC (888-822-6642) in the US or +45 70 23 04 05 in Europe.
About Taconic Biosciences, Inc.
Taconic Biosciences is a global provider of genetically engineered rodent models and services. Founded in 1952, Taconic helps the biotechnology and pharmaceutical communities acquire, custom generate, breed, precondition, test, and distribute highly relevant research models worldwide. Specialists in genetically engineered mouse and rat models, integrated model design and breeding services, and precision research mouse models, Taconic operates three service laboratories and six breeding facilities in the U.S. and Europe and maintains distributor relationships in Asia.
Information om Marketwired
Følg pressemeddelelser fra Marketwired
Ved at skrive dig op her, vil du modtage pressemeddelelser på mail når de udsendes. Indtast din mail og følg instruktionerne. Det er ligeså let at melde sig fra igen.
Flere pressemeddelelser fra Marketwired
Algeco Scotsman17.10.2017 22:43 | pressemeddelelse
Algeco Scotsman Announces Additional Notes Funding
1025Connect17.10.2017 20:51 | pressemeddelelse
1025 Old Country Road Announces $14 Million Growth Financing
RenalGuard Solutions, Inc.17.10.2017 17:24 | pressemeddelelse
RenalGuard Solutions Names Andrew Halpert Chief Technology Officer
Bombardier Inc.17.10.2017 01:46 | pressemeddelelse
Media Advisory: Bombardier to Hold a Press Conference and Conference Call
Bombardier Inc. and Airbus SE17.10.2017 01:00 | pressemeddelelse
Airbus and Bombardier Announce C Series Partnership
RenalGuard Solutions, Inc.12.10.2017 14:01 | pressemeddelelse
Initial Clinical Results Show Feasibility and Safety of RenalGuard Use to Reduce Risk of Cardiac Surgery-Associated Acute Kidney Injury
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum